Advertisement #1
Home Tags Pembrolizumab

Tag: pembrolizumab

Tebentafusp Significantly Improves Overall Survival in Patients With Metastatic Uveal Melanoma

Peter Hofland, Ph.D -
Merck | MSD Exhibition booth at the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Combination of SLC-391 + Pembrolizumab Enters Clinical Trial Advanced NSCLC

Peter Hofland, Ph.D -

The History, Reality and Promise of Immunotherapy for Cancer

Daniel A. Vorobiof, MD -

Pembrolizumab + Axitinib Outperforms Sunitinib in Treatment of Metastatic Renal Cell...

Danielle Garcia -
Merck | MSD Exhibition booth at the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

FDA Approves Pembrolizumab in Adult Patients With Relapsed or Refractory Classical...

Editorial Team -

ESMO 2020: First-in-class MK-4830 Antibody Targeting ILT4 Shows Promising Preliminary...

Editorial Team -
Merck | MSD Exhibition booth at the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Pembrolizumab Approved for Treatment Advanced Cutaneous Squamous Cell Carcinoma

Peter Hofland, Ph.D -
Seattle Genetics. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO). In the back of the booth the enfortumab vedotin presentation.

Potential Accelerated Approval Enfortumab Vedotin + Pembrolizumab in Metastatic Urothelial Cancer

Peter Hofland, Ph.D -

Combination Enfortumab Vedotin + Pembrolizumab Granted Breakthrough Therapy in Bladder Cancer

Peter Hofland, Ph.D -

Enfortumab Vedotin + Pembrolizumab Shrink Tumors in the Majority of Bladder...

Peter Hofland, Ph.D -
123Page 1 of 3

LATEST NEWS

Advertisment #12
© 2001 - 2020 Sunvalley Communication, LLC. All Rights Reserved.